1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

TTSE:4521
3,860.00
JPY
+15.00
(+0.39%)
156.77BMarket Cap
Nov 09Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2,085.68
2,253.14
2,637.29
2,486.25
2,432.22
2,361.61
2,279.87
1,942.96
2,002.05
1,942.56
1,909.23
2,464.1
2,027.67
- -
Basic EPS, GAAP
228.27
290.88
510.54
536.71
470.55
445.78
494.89
347.37
251.44
144.79
212.67
365.42
56.55
- -
Free Cash Flow per Basic Share
270.52
304.97
575.91
316.24
489.62
476.53
645.53
313.4
265.39
187.56
10.87
665.27
-435.28
- -
Dividend per Share
92.29
102.3
131.92
153.28
150.36
150.5
150.64
150.58
150.46
150.36
149.92
188.62
171.4
- -
Book Value per Share
1,611.72
1,861.07
2,170.56
2,511.64
2,824.28
3,049.75
3,301.04
3,555.89
3,642.28
3,636.14
3,796.04
3,974.44
3,898.17
3,898.17
Tangible Book Value per Share
1,597.56
1,849.62
2,161.6
2,502.54
2,810.59
3,035.88
3,290.4
3,539.58
3,424.5
3,456.25
3,599
3,395.65
3,256.71
3,256.71
Basic Weighted Avg Shares
43
42
41
41
40
40
39
39
38
38
38
38
38
38
Sales/Revenue/Turnover
88,949
93,895
109,218
101,991
98,432
94,167
89,234
74,979
76,034
72,984
72,044
94,035
76,871
- -
Operating Margin (%)
17.85
21.97
32.19
30.11
27.94
26.12
29.71
23.73
22.45
10.96
13.21
22.37
-1.17
- -
Depreciation Expense
2,538
2,400
2,242
1,937
2,124
2,153
2,312
2,318
2,486
2,568
2,753
2,554
3,325
- -
Net Income, GAAP
9,735
12,122
21,143
22,017
19,043
17,775
19,370
13,405
9,549
5,440
8,025
13,945
2,144
- -
Effective Tax Rate (%)
37.18
34.86
40.09
29.19
31.22
28.68
27.16
28.15
31.23
20.2
18.07
28.25
7.26
- -
Profit Margin (%)
10.94
12.91
19.36
21.59
19.35
18.88
21.71
17.88
12.56
7.45
11.14
14.83
2.79
- -
Working Capital
30,445
38,647
55,130
66,474
72,458
76,151
86,681
92,386
91,564
89,065
87,950
81,039
73,248
73,248
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
68,094
77,098
89,874
102,654
113,873
121,130
128,467
136,256
138,323
136,835
143,755
152,634
147,617
147,617
Return on Invested Capital (%)
12.96
16.54
22.3
20.52
16.27
13.93
14.62
9.21
8.18
4.44
5.37
9.69
-0.53
- -
Return on Capital (%)
13.23
15.65
23.99
22
16.99
14.65
15.06
9.85
6.77
3.86
5.58
9.18
1.42
- -
Return on Common Equity (%)
14.46
16.7
25.33
22.87
17.59
15.13
15.52
10.13
6.97
3.97
5.73
9.41
1.43
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
3,850
3,850
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
38
Market Capitalization
144,644
138,334
156,775

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
98,757
94,051
Cash, Cash Equivalents & STI
- -
57,104
50,705
Accounts Receivable, Net
- -
21,762
19,378
Inventories
- -
18,156
19,115
Total Current Liabilities
- -
22,431
20,803
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,850
3,850
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.2%
1.68%
-3.29%
Free Cash Flow
577.01%
1,157.26%
-165%
Net Income, GAAP
-7.3%
-7.03%
-84.63%
Sales/Revenue/Turnover
-2.73%
1.68%
-18.25%
Total Cash Common Dividend
2.21%
2.97%
-9.72%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18,150
18,021
18,514
17,359
72,044
2025
- -
- -
- -
- -
94,035
2026
- -
- -
- -
- -
76,871

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
66.98
41.29
68.84
35.65
212.67
2025
- -
- -
- -
- -
365.42
2026
- -
- -
- -
- -
56.55

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
149.92
2025
- -
- -
- -
- -
188.62
2026
- -
- -
- -
- -
171.4

Company Description

Company Profile APIChatGPT
CEO
Hiroyuki Horiuchi
Full Time Employees
1,114
Sector
Health technology
Industry
Pharmaceuticals: major
Address
28-8, Honkomagome 2-chome Tokyo TY Japan 113-8650
IPO Date
Oct 2, 1961
Website
kaken.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kaken Pharmaceutical Co., Ltd. develops, manufactures and markets prescription pharmaceuticals, medical devices, agrochemicals and engages in real estate operations primarily in Japan. The company offers core pharmaceutical products including Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock, a treatment for primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; and Hernicore, a treatment for lumbar disc herniation; as well as the medical device Seprafilm, a post-operative adhesion barrier. It focuses on therapeutic areas such as dermatology, orthopedics, ophthalmology and wound care, serving healthcare professionals and patients through prescription channels, while its agrochemical segment provides fungicides, paddy rice herbicides and feed additives. Founded in 1948 from the reorganization of the Institute of Physical and Chemical Research (Riken) and headquartered in Tokyo, Japan, Kaken Pharmaceutical maintains a collaboration and licensing agreement with Alumis Inc. to develop, manufacture and commercialize ESK-001, a selective oral tyrosine kinase 2 inhibitor for dermatology indications in Japan. In December 2024, the company entered a purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for approximately $100 million, marking a strategic expansion into new assets. Under its Long-Term Business Plan 2031 launched in 2022, Kaken pursues global growth in dermatology and orthopedics through enhanced research, overseas expansion and operational transformation, with pharmaceuticals comprising over 96% of consolidated net sales complemented by stable real estate income from Bunkyo Green Court.